CORT Corcept Therapeutics Inc

$CORT Shorts have knocked Corcept stock from $126 to $110 by slamming at open and close every day. They use algorithms to trick automated trading systems and unsophisticated investors. This creates opportunity for the intelligent investor. There are at least 5 distinct catalysts coming up in next two months, any one of which can spike stock north of $200 overnight. (1) Positive cancer results. CORT just had the second best oncology launch in history. More positive data before year end would expand the indication from $1 to $5 billion in potential market. (2) Relacorilant approval in Cushing’s. FDA rejection is expected and baked in to the current share price. A FDA reversal and surprise approval could add $75 to stock overnight. (3) Positive MASH results. Game changer. MASH is huge indication, and if CORT has a viable MASH drug they will likely great taken out well north of $200/sh. This could add $100 to stock overnight. Big pharma needs this.

$CORT Crazy triple-witching with 17M shares traded last Friday - $1.8B worth of the stock changed hands. With Relacorilant/CS' FDA approval and Lifyorli/PROC's EMA approval just around the corner, we should see $150 SP by year end. Then comes 2027 - Dazucorilant and Miricorilant rises from the horizon. We should see $250 to $300 SP by EOY 2027, or be acquired at such before then. GLTA and cheers!

$CORT looks like the Monarch ph2b mash study was completed 9/29. I wonder how long before we see top line data? Should be before next earnings report I hope.

$CORT With 9.4M shares shorted, which is about 9% outstanding or 11% float, we will only trade sideways for a while until the next catalysts such as Relacorilant/CS approval in US, Lifyorli approval in EU, and/or Q3 ER - all in 2027. These catalysts should advance SP to north of $150. More exciting are the clinical advancement of Dazucorilant/ALS and Miricorilant/MASH to P3 trials. Hopefully, at least one of the two will be in H1/27, or both. The initiation of these two P3 trials will further advance SP to above $200. Then in 2028, we should see all four franchises firing - CS, PROC, ALS, and MASH, which are all $B- dollar blockbuster drugs. If not acquired and no split by then, we should see SP reaches north of $300. GL & cheers!

$CORT Short-term catalysts are coming: Early Nov. - Q3 ER (Lifyorli sales ramp, record revenue, clinical development updates) Mid Dec. - Relacorilant/CS approval (Resubmitted on on 6/17, FDA accelerated approval possible in Nov.) EOY 2026 - Start of P3 trial for Dazucorilant/ALS EOY 2027 - Readout of Miricorilant/MASH P2b trial With only 2.5 months left, a busy catalyst calendar indeed. These will propel the SP to $150 territory or higher. GLTA and cheers!

$CORT looks like that 10% of volume spike Friday at close was being added to the s&p 400 mid according to gemini. We might get some volatility Monday Tuesday due to others rebalancing.

$CORT interesting that back in 2012 after fda approval analysts were only targeting $7. $10K back in 2012 would be worth $900K today Much smaller market too than… $CELC Cort doubled in a year after fda approval and then tripled in 3 years

$CORT Maduck retires. Did he do so because his 10b5-1 recently reached a set price (maybe 125) and cashed him out of 170k options or did his 10b5-1 have him exercise 170K options regardless of price in contemplation of retirement ?